<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02379793</url>
  </required_header>
  <id_info>
    <org_study_id>LP0076-1080</org_study_id>
    <nct_id>NCT02379793</nct_id>
  </id_info>
  <brief_title>Skin Irritation Test of LEO 80185 Gel in Healthy Japanese Subjects</brief_title>
  <official_title>Skin Irritation Test of LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate skin irritation of LEO 80185 gel, gel vehicle and&#xD;
      Liquid Paraffin in healthy Japanese male subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skin irritation measured as -, +/-, +, ++, +++, ++++</measure>
    <time_frame>4 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Skin and Connective Tissue Diseases</condition>
  <arm_group>
    <arm_group_label>LEO 80185 gel, vehicle, liquid paraffin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject has all 3 treatments applied topically at the same time. However, the location on which the treatments are applied is randomised in an investigator blinded manner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 80185 gel, vehicle, liquid paraffin</intervention_name>
    <description>Each subject has all 3 treatments applied at the same time. Each treatment is applied once to 2 locations on the subject.</description>
    <arm_group_label>LEO 80185 gel, vehicle, liquid paraffin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent has been obtained.&#xD;
&#xD;
          2. Healthy Japanese male subjects.&#xD;
&#xD;
          3. Aged 20 to 40 years inclusive.&#xD;
&#xD;
          4. Subjects without signs of skin irritation/disease/disorders/symptoms or blemishes on&#xD;
             test sites (e.g. erythema, dryness, roughness, scaling, scars, moles, sunburn).&#xD;
&#xD;
          5. Subjects without a significant abnormality, as judged by the (sub)investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Body Mass Index outside the range 18-25 kg/mÂ²&#xD;
&#xD;
          2. History of alcohol or drug abuse.&#xD;
&#xD;
          3. History of allergic reaction to any medications.&#xD;
&#xD;
          4. Any disease that could in any way confound assessment of the test sites.&#xD;
&#xD;
          5. Known or suspected hypersensitivity to any component of LEO 80185 gel.&#xD;
&#xD;
          6. Known or suspected hepatic, renal or cardiac disorders.&#xD;
&#xD;
          7. Known or suspected disorders of calcium metabolism associated with hypercalcaemia or&#xD;
             albumin-corrected serum calcium above the reference range from the sample taken during&#xD;
             screening.&#xD;
&#xD;
          8. Subjects suspected of infection based on the infection testing results from the sample&#xD;
             taken during screening (Hepatitis B surface antigen, HCV antibody, HIV&#xD;
             antigen/antibody, serological test for syphilis).&#xD;
&#xD;
          9. Use of systemic, locally injected or inhaled corticosteroids within 4 weeks of Day 1.&#xD;
&#xD;
         10. Use of vitamin D or calcium supplements, or systemic vitamin D analogues within 4&#xD;
             weeks of Day 1.&#xD;
&#xD;
         11. Use of any medication (systemic or topical) within 2 weeks of Day 1.&#xD;
&#xD;
         12. Subjects who have received treatment with any non-marketed drug substance (i.e. an&#xD;
             agent which has not yet been made available for clinical use following registration)&#xD;
             within 4 weeks or 5 half-lives of Day 1, whichever is longest.&#xD;
&#xD;
         13. Current participation in any other interventional clinical trial.&#xD;
&#xD;
         14. Previously enrolled in this clinical trial.&#xD;
&#xD;
         15. Previous or current photo-induced or photo-aggravated disease (e.g. abnormal response&#xD;
             to sunlight).&#xD;
&#xD;
         16. Exposure to excessive or chronic ultraviolet radiation (e.g. sunlight, sun lamps,&#xD;
             tanning booths or photo-therapy) within 4 weeks of Day 1.&#xD;
&#xD;
         17. Subjects (or their partner) not using an adequate method of contraception during the&#xD;
             trial (Day 1-4).&#xD;
&#xD;
         18. In the opinion of the (sub)investigator, participation in the trial is inappropriate.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical Co. LTA HAKATA Clinic</name>
      <address>
        <city>Random Square 5F, 6-18 Tenyamachi, Hakata-ku</city>
        <state>Fukuoka</state>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>February 26, 2015</study_first_submitted>
  <study_first_submitted_qc>March 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2015</study_first_posted>
  <last_update_submitted>June 13, 2016</last_update_submitted>
  <last_update_submitted_qc>June 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LEO 80185 gel</keyword>
  <keyword>calcipotriol</keyword>
  <keyword>betamethasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Connective Tissue Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mineral Oil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

